R C Petersen
Overview
Explore the profile of R C Petersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
216
Citations
26789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boots E, Frank R, Fan W, Christianson T, Kremers W, Stricker J, et al.
J Prev Alzheimers Dis
. 2024 Oct;
11(5):1467-1479.
PMID: 39350394
Background: Easily accessible and self-administered cognitive assessments that can aid early detection for Alzheimer's disease (AD) dementia risk are critical for timely intervention. Objectives/design: This cross-sectional study investigated continuous associations...
2.
Angioni D, Cummings J, Lansdall C, Middleton L, Sampaio C, Gauthier S, et al.
J Prev Alzheimers Dis
. 2024 Oct;
11(5):1219-1227.
PMID: 39350367
Recent positive results of three phase III anti-amyloid monoclonal antibody trials are transforming the landscape of disease-modifying therapeutics for Alzheimer's disease, following several decades of failures. Indeed, all three trials...
3.
Erickson C, Karlawish J, Grill J, Harkins K, Landau S, Rivera-Mindt M, et al.
J Prev Alzheimers Dis
. 2024 Feb;
11(2):294-302.
PMID: 38374735
Background: Prior studies of Alzheimer's disease (AD) biomarker disclosure have answered important questions about individuals' safety after learning and comprehending their amyloid PET results; however, these studies have typically employed...
4.
Cummings J, Apostolova L, Rabinovici G, Atri A, Aisen P, Greenberg S, et al.
J Prev Alzheimers Dis
. 2023 Jun;
10(3):362-377.
PMID: 37357276
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild...
5.
Rhodus E, Aisen P, Grill J, Rentz D, Petersen R, Sperling R, et al.
J Prev Alzheimers Dis
. 2022 Oct;
9(4):665-671.
PMID: 36281670
Background: The COVID-19 pandemic created challenges in clinical research operations that required immediate and lasting changes. Ojbectives: The purpose of this study was to explore adaptations to clinical trial research...
6.
7.
Gonzales M, Garbarino V, Marques Zilli E, Petersen R, Kirkland J, Tchkonia T, et al.
J Prev Alzheimers Dis
. 2022 Jan;
9(1):22-29.
PMID: 35098970
Preclinical studies indicate an age-associated accumulation of senescent cells across multiple organ systems. Emerging evidence suggests that tau protein accumulation, which closely correlates with cognitive decline in Alzheimer's disease and...
8.
Weiner M, Aisen P, Beckett L, Green R, Jagust W, Morris J, et al.
J Prev Alzheimers Dis
. 2021 Sep;
8(4):391-392.
PMID: 34585209
No abstract available.
9.
Bock J, Hara J, Fortier D, Lee M, Petersen R, Shankle W
J Prev Alzheimers Dis
. 2021 Feb;
8(2):123-126.
PMID: 33569557
Background: Recent Alzheimer's disease (AD) trials have faced significant challenges to enroll pre-symptomatic or early stage AD subjects with biomarker positivity, minimal or no cognitive impairment, and likelihood to decline...
10.
Stricker N, Lundt E, Alden E, Albertson S, Machulda M, Kremers W, et al.
J Prev Alzheimers Dis
. 2020 Feb;
7(1):21-28.
PMID: 32010922
Background: The Cogstate Brief Battery (CBB) is a computerized cognitive assessment that can be completed in clinic or at home. Design/Objective: This retrospective study investigated whether practice effects / performance...